MPR Weekly Dose 98 - FDA Committee Vote on Vaccines for Children; Booster Efficacy Results; Shingrix Recommendations; Novel Treatment for Macular Edema; Pepaxto Withdrawn

The FDA votes on whether the Pfizer-BioNTech vaccine should be authorized in 5 to 11 year olds; The Moderna vaccine elicits strong antibody responses in pediatrics; Trial results shed light on booster dose efficacy; Shingrix is recommended for immunocompromised patients; A novel treatment is approved for macular edema associated with uveitis; And Pepaxto is withdrawn following new findings.